IGC Pharma (IGC) EBITDA (2010 - 2025)

IGC Pharma (IGC) has 16 years of EBITDA data on file, last reported at -$1.8 million in Q3 2025.

• EBITDA for Q3 2025 came in at -$1.8 million, down 6.24% year-over-year; the trailing twelve-month figure through Sep 2025 was -$6.5 million (up 48.43% YoY), and the FY2026 annual result was -$2.4 million, up 66.3% from the prior year.
• EBITDA slipped to -$1.8 million in Q3 2025 per IGC's latest filing, from -$1.6 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.2 million in Q1 2025 and troughed at -$6.7 million in Q1 2022.
• A 5-year average of -$2.8 million and a median of -$2.4 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2021 and 2024: EBITDA plunged 185.41% in 2021, then jumped 66.85% in 2024.
• A 5-year view of EBITDA shows it stood at -$2.3 million in 2021, then decreased by 0.26% to -$2.3 million in 2022, then sank by 141.17% to -$5.6 million in 2023, then jumped by 66.85% to -$1.8 million in 2024, then climbed by 0.38% to -$1.8 million in 2025.
• Business Quant data shows IGC's EBITDA at -$1.8 million in Q3 2025, -$1.6 million in Q2 2025, and -$1.2 million in Q1 2025.